The ousting of McDonald’s chief Steve Easterbrook for a consensual relationship with an employee dented the shares. But investors gain too when companies lay down rules to protect workers and apply them evenly. Other companies haven’t been so responsiv…
Nov 1 – Pharma giant Amgen is buying a fifth of China biotech star BeiGene for $2.7 bln. A 36% premium seems steep when the target has just shaken off a short-seller attack. But it’s a chance to crack a growing market for cancer drugs, Katrina Hamlin t…
Oct 31 – Altria is writing down $4.5 billion of its investment in vape-pen maker Juul. The e-cigarette maker is facing tougher regulations in the United States that could slow sales and bite into profits. Robert Cyran explains why Altria may still be t…
The U.S. group’s shares had their best day in a decade thanks to boss Larry Culp’s nips, tucks and trims. The company is cutting debt, and its jet and healthcare units are growing. Culp looks pedestrian compared with his predecessors, and John Foley ar…
Though it’s one of the few profitable food-delivery outfits, Grubhub is feeling the pain from cash-rich, profit-poor rivals like Uber Eats and DoorDash. As Jennifer Saba explains, the competition means Grubhub is going to have to do things it doesn’t w…
Activist investor Elliott Management quickly persuaded the $270 billion telecom to give in to its demands for asset sales and better governance. John Foley explains why the deal is a victory not just for the two sides, but for shareholders in other com…
Tesla’s third-quarter net profit cheered investors: so too did news that its China factory is almost ready for production. But Elon Musk faces a rough ride ahead, Katrina Hamlin tells Pete Sweeney. The country’s car sales are slowing, just as he reposi…
Twitter fumbled how it handles advertising in the third quarter, sending the company’s stock down nearly 20%. As Robert Cyran explains, the service has a habit of disappointing investors, calling its ability to fix its business into question.
Boeing CEO Dennis Muilenburg is in the hot seat. The head of the airplane maker is facing production cuts, rising debt and a grilling in the U.S. Congress over the 737 MAX crashes. But investors reacted well to disappointing third-quarter earnings. Ant…
Shares of Biogen skyrocketed roughly 40 percent Tuesday after the biotech company said it will seek approval for an Alzheimer’s treatment after abandoning the drug earlier this year. Freddie Joyner has the story.